A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
Robert Holloway -
Sponsor
GOG Partners & KaryoPharm Therapeutics
The purpose of this Phase 3 study is to compare the PFS of patients receiving Selinexor maintenance therapy after prior systemic therapy to the PFS of patients receiving placebo as maintenance therapy for TP53 wt advanced or recurrent EC and to confirm the subpopulation data observed in the SIENDO study
Enrollment Form
This study is currently enrolling.